source
- Beacon eye gene therapy hits mark in late-stage studyBeacon claimed the findings represent the first time a treatment for X-linked retinitis pigmentosa, a rare and potentially blinding condition, met its main goal in a pivotal trial.
- Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecastsDeals for Chinese radiopharmaceutical assets have been rare to date and there is a limited pool of potential Western buyers available, Sleuth said.BioSpace · 1mo ago↗ source